ProCE Banner Activity

Reducing Disparities in Lupus and Lupus Nephritis Care

Podcast Episodes

Drs Karen Costenbader and Brad Rovin discuss current disparities in lupus and lupus nephritis, including prevalence, social determinants of health, medication adherence, representation in clinical trials, and what healthcare professionals can do to address these disparities.

Released: June 02, 2022

Expiration: June 01, 2023

Share

Faculty

Karen H. Costenbader

Karen H. Costenbader, MD, MPH

Professor of Medicine
Department of Medicine
Harvard Medical School
Director, Lupus Program
Division of Rheumatology, Inflammation and Immunity
Brigham and Womens Hospital
Boston, Massachusetts

Brad H. Rovin

Brad H. Rovin, MD

Professor and Director, Division of Nephrology
The Lee A. Hebert Professor of Nephrology
Medical Director
, The Ohio State Center for Clinical Research Management
The Ohio State University Wexner Medical Center
Columbus, Ohio

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

This educational activity is supported by an educational grant from

GlaxoSmithKline

Faculty Disclosure

Primary Author

Karen H. Costenbader, MD, MPH

Professor of Medicine
Department of Medicine
Harvard Medical School
Director, Lupus Program
Division of Rheumatology, Inflammation and Immunity
Brigham and Womens Hospital
Boston, Massachusetts

Karen H. Costenbader, MD, MPH, has disclosed that she has received research funding from Exagen, Gilead Sciences, and Merck and consulting fees from Amgen, AstraZeneca, GlaxoSmithKline, Janssen, and Lilly.

Brad H. Rovin, MD

Professor and Director, Division of Nephrology
The Lee A. Hebert Professor of Nephrology
Medical Director
, The Ohio State Center for Clinical Research Management
The Ohio State University Wexner Medical Center
Columbus, Ohio

Brad H. Rovin, MD, has disclosed that he has received funds for research from Aurinia Pharmaceuticals, Biocryst, Biogen Idec, Bristol-Myers Squibb, Callidatis, Chemocentryx, Human Genome Sciences, Idorsia, and Lucin and consulting fees from Admirx, Alexion, AstraZeneca, Aurinia Pharmaceuticals, Biocryst, Biogen Idec, Bristol-Myers Squibb, Callidatis, Chugai Pharma, Corrona, EMD Serono, Genentech/Hoffman-La Roche, Janssen, Kezar Life Sciences, Lilly, Morphosys, Novartis, Omeros, Otsuka, Pfizer, Principia, and Travere Therapeutics.